文献速递妇科

修订版FIGO2023分期结合分子分型在子宫内膜癌中的应用价值

Utility of the revised FIGO2023 staging with molecular classification in endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2023-09-23

本研究纳入1997至2019年在国家癌症中心医院接受初次手术且病理诊断为子宫内膜癌的265例患者,比较FIGO2008、未结合分子分型的FIGO2023及结合分子分型的FIGO2023m三种分期的拟合优度与区分能力。结果显示FIGO2023m的AIC最低(455.925)、C-index最高(0.768),术后1年内时间依赖ROC曲线更优;在IIIC期,p53异常患者5年总生存率显著低于p53野生型(24.3% vs 83.7%,p=0.0005)。结论认为FIGO2023m区分能力最佳,p53状态为不良预后因素,在可行时可加入分子亚型以改善各期预后预测。

要点

  • FIGO2023m的AIC最低(455.925),C-index最高(0.768),优于FIGO2023与FIGO2008。
  • IIIC期p53异常患者5年总生存率24.3%,低于p53野生型的83.7%(p=0.0005)。
  • 作者认为在可行时可将分子亚型加入分期标准以改善各期预后预测。

核心结论

  • FIGO2023m相比FIGO2008和FIGO2023具有最佳的区分能力。
  • 即使在晚期阶段,p53状态仍是不良预后因素。
  • 作者认为在可行时可将分子亚型加入分期标准,以在所有分期中实现更好的预后预测。

研究设计与样本

  • 研究纳入1997年至2019年在国家癌症中心医院接受初次手术且病理诊断为子宫内膜癌的265例患者。
  • 比较FIGO2008、未结合分子分型的FIGO2023及结合分子分型的FIGO2023m三种分类系统,采用Harrell一致性指数(C-index)、赤池信息准则(AIC)和时间依赖受试者工作特征(ROC)曲线进行评价。
  • C-index越高、AIC越低表示模型越准确。

主要发现

  • FIGO2023m的AIC值最低(FIGO2023m:455.925;FIGO2023:459.162;FIGO2008:457.901)。
  • FIGO2023m的C-index最高(FIGO2023m:0.768;FIGO2023:0.743;FIGO2008:0.740)。
  • FIGO2023m在手术切除后1年内的时间依赖ROC曲线更优。
  • 在IIIC期,p53异常患者的5年总生存率低于p53野生型患者(24.3% vs 83.7%,p=0.0005)。

关键数值与推荐

  • FIGO2023m的AIC为455.925,FIGO2023为459.162,FIGO2008为457.901。
  • FIGO2023m的C-index为0.768,FIGO2023为0.743,FIGO2008为0.740。
  • IIIC期p53异常患者5年总生存率为24.3%,p53野生型患者为83.7%(p=0.0005)。

临床怎么用

  • 作者认为在可行时可将分子亚型加入分期标准,以在所有分期中实现更好的预后预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Molecular classification was introduced in endometrial cancer staging following the transition of the International Federation of Gynecology and Obstetrics (FIGO) 2008 to FIGO2023. In the early stages, p53 abnormal endometrial carcinoma with myometrial involvement was upstaged to stage IICm, in addition to the downstaging of POLE mutation endometrial cancer to stage IAm. This study compared the goodness of fit and discriminatory ability of FIGO2008, FIGO2023 without molecular classification (FIGO2023), and FIGO2023 with molecular classification (FIGO2023m); no study has been externally validated to date. METHODS: The study included 265 patients who underwent initial surgery at the National Cancer Center Hospital between 1997 and 2019 and were pathologically diagnosed with endometrial cancer. The three classification systems were compared using Harrell's concordance index (C-index), Akaike information criterion (AIC), and time-dependent receiver operating characteristic (ROC) curves. A higher C-index score and a lower AIC value indicated a more accurate model. RESULTS: Among the three classification systems, FIGO2023m had the lowest AIC value (FIGO2023m: 455.925; FIGO2023: 459.162; FIGO2008: 457.901), highest C-index (FIGO2023m: 0.768; FIGO2023: 0.743; FIGO2008: 0.740), and superior time-dependent ROC curves within 1 year after surgical resection. In the stage IIIC, patients with p53 abnormalities had considerably lower 5-year overall survival than those with a p53 wild-type pattern (24.3% vs. 83.7%, p = 0.0005). CONCLUSIONS: FIGO2023m had the best discriminatory ability compared with FIGO2008 and FIGO2023. Even in advanced stages, p53 status was a poor prognostic factor. When feasible, molecular subtypes can be added to the staging criteria to allow better prognostic prediction in all stages.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kobayashi-Kato M, Fujii E, Asami Y, et al. Utility of the revised FIGO2023 staging with molecular classification in endometrial cancer. Gynecol Oncol. 2023. PMID: 37748269. doi:10.1016/j.ygyno.2023.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。